CLOs on the Move

AavantiBio

www.aavantibio.com

 
AavantiBio is a pre-clinical biopharmaceutical company committed to developing and commercializing novel gene transfer and gene editing therapies for the treatment of rare and ultra-rare genetic diseases. The company is rapidly building a diverse portfolio of gene transfer and gene editing therapies to target debilitating genetic diseases for which the unmet medical need is high for which there are typically no approved therapies treating the underlying disease. AavantiBio is headquartered in Cambridge, MA with additional locations in Gainesville, FL. We are looking for exceptional individuals who share our passion for developing novel therapies to treat rare diseases and advancing the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aavantibio.com
  • 245 First Street Riverview II, 18th Floor
    Cambridge, MA USA 02142
  • Phone: n/a

Executives

Name Title Contact Details
David Howton
General Counsel Profile
Stephen Brown
Senior Director, Intellectual Property Profile

Similar Companies

Ginkgo Bioworks

At Ginkgo Bioworks we are expanding the role of biology in our world.Nature`s biodiversity holds answers to challenges in health, energy, food, materials, and more. Organism Engineers at Ginkgo learn from Nature to develop new organisms that replace technology with biology.

National Institutes of Health

The National Institutes of Health (NIH) is the largest biomedical research agency in the world, conducting research in its own laboratories, supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research ins...

CPS Instruments

CPS Instruments is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Microbion

Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.

Assurex Health

Assurex Health is a personalized medicine company that specializes in helping physicians determine the right medication for individual patients who have Behavioral Health disorders. The GeneSight analysis is based on pharmacogenomics, the study of the genetic factors that influence an individual`s response to drug treatments.